<DOC>
	<DOCNO>NCT02634515</DOCNO>
	<brief_summary>This study healthy volunteer aim demonstrate similar PK PD property new short-acting human soluble insulin , Julphar Insulin R , already approve reference insulin , Huminsulin® Normal . The trial participant receive study treatment two separate dosing day .</brief_summary>
	<brief_title>Pharmacokinetic ( PK ) Bioequivalence Pharmacodynamics Julphar Insulin R Huminsulin® Normal</brief_title>
	<detailed_description>The daily injection insulin necessity many patient diabetes mellitus order treat hyperglycemia . Julphar Insulin R Huminsulin® Normal soluble insulin intend subcutaneous administration consist neutral solution contain recombinant human insulin active ingredient . The new insulin , Julphar Insulin R biosimilar Huminsulin® Normal . Demonstration bioequivalence PK PD perspective two insulin necessary achieve market approval Julphar Insulin R .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Signed date informed consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject ) . Healthy male female subject . Age 18 55 year , inclusive . Body Mass Index ( BMI ) 18.5 28.0 kg/m^2 , inclusive . Fasting plasma glucose ( FPG ) ≤5.6 mmol/L ( 100 mg/dL ) . Known suspected hypersensitivity trial product ( ) relate product . Receipt IMP within 3 month prior screen . Any history presence life threaten disease ( i.e. , cancer except basal cell skin cancer squamous cell skin cancer ) , clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic , haematological , neurological , musculoskeletal , articular , psychiatric , systemic , ocular , gynaecologic ( female ) , infectious disease , sign acute illness judge Investigator . Surgery within 12 week start study blood donation 500 mL ( considerable blood loss ) plasma donation within last 3 month . Increased risk thrombosis , e.g. , subject history deep leg vein thrombosis family history deep leg vein thrombosis , judge Investigator . Haemoglobin &lt; 8.0 mmol/L ( male ) &lt; 6.4 mmol/L ( female ) , total leukocyte count &lt; 3.0 x 10^9/L , thrombocytes &lt; 100 x 10^9/L , serum creatinine level ≥ 126 µmol/L ( male ) ≥ 111 µmol/L ( female ) , alanine aminotransferase ( ALT ) &gt; 2 x upper limit normal ( ULN ) , bilirubin &gt; 3 x ULN , alkaline phosphatase &gt; 2 x ULN . Supine blood pressure ( BP ) screening ( rest 5 minute supine position ) outside range 90 140 mmHg systolic BP 50 90 mmHg diastolic BP ( exclude whitecoat hypertension ; therefore , repeat measurement show value within range , subject include trial ) and/or rest supine pulse &lt; 50 beat per minute . Clinically significant abnormal standard 12lead ECG 5 minute rest supine position screening , judge Investigator . Any disease condition , opinion Investigator , would represent unacceptable risk subject 's safety . Subject know positive Hepatitis Bs antigen ( HBsAg ) Hepatitis C antibody ( diagnose active hepatitis accord local practice ) test positive screening human immunodeficiency virus Type 1 ( HIV1 ) antibody , HIV Type 2 ( HIV 2 ) antibody , HIV1 antigen accord locally use diagnostic testing . History multiple and/or severe allergy drug food history severe anaphylactic reaction . Likelihood require treatment study period drug permit clinical study protocol . Any medication ( prescription nonprescription drug ) within 14 day first trial drug administration , exception stable treatment thyroid hormone , paracetamol occasional use treat pain , female , exception hormonal contraception menopausal hormone replacement therapy . Significant history alcoholism drug/chemical abuse per Investigator 's judgement positive result urine drug/alcohol screen screen visit consume 21 unit alcohol per week ( 1 unit alcohol equal approximately 330 mL beer , 1 glass wine ( 120 mL ) , 40 mL spirit ) . Smoker ( define subject smoke 5 cigarette equivalent per day ) able willing refrain smoking use nicotine substitute product 1 day inpatient period/trial . Subject mental incapacity language barrier preclude adequate understanding cooperation , opinion Investigator general practitioner , participate trial . Potentially noncompliant uncooperative trial , judge Investigator . Female pregnant , breast feeding intend become pregnant childbearing potential use adequate contraceptive method ( adequate contraceptive measure define surgical sterilisation , implant , injectables , combine oral contraceptive , hormonal intrauterine device , sexual abstinence , vasectomised partner ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>soluble human insulin , biosimilar</keyword>
</DOC>